Conclusion
tumor
TUMOR
In conclusion, our study illustrates that infusion of autologous GD2-specific 4SCAR-T cells into patients with GBM via two different routes is safe and well-tolerated. In addition, GD2-specific 4SCAR-T cells partially mediate antigen loss and activate immune responses in the tumor microenvironment. Although extended lifespan and specific antigen loss of GD2 were observed in some patients, the clinical benefit could not be determined from this study due to the small sample size. Our initial clinical trial highlights the safety of GD2-specific 4SCAR-T cells in targeting GBM, and further phase 2 studies evaluating GD2-specific 4SCAR-T cells are warranted.